Journavx has been specifically approved for the treatment of moderate-to-severe acute pain, which often results from injury, surgery, illness, trauma or painful medical procedures, ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Journavx showed a “statistically significant superior reduction in pain” when compared to a placebo in two randomized trials of acute surgical pain, according to the FDA.

Journavx targets specific proteins in the body called sodium channels. Sodium channels help send pain signals to your brain. Your brain then processes how you will experience and respond to the pain.

Journavx (suzetrigine) is a new nonopioid medication manufactured by Vertex Pharmaceuticals to help treat and manage moderate to severe acute pain.

But Journavx has its limitations, experts said, as the drug is not approved yet for chronic pain and at $15.50 per pill is more expensive than most opioids. Adam Birkenstock, ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous Vertex Pharmaceuticals A new painkiller has been approved for the first time in ...

Significantly, Journavx didn’t provide better pain relief than the opioid combination in one of the trials and was inferior to the combination in the other trial.

Alyftrek and Journavx — The Two Big Launches. According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyftrek and Journavx.

Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 years. [READ: Understanding the Impact of Health Conditions and Medications on Seniors] ...

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years.